fenofibrate has been researched along with celecoxib in 18 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 5 (27.78) | 29.6817 |
2010's | 13 (72.22) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H | 1 |
Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Doak, AK; Prusiner, SB; Shoichet, BK; Wille, H | 1 |
Ekins, S; Williams, AJ; Xu, JJ | 1 |
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Anastasiadis, PZ; Beard, J; Das, P; Dodson, M; Eriksen, JL; Fauq, A; Golde, TE; Kache, R; Khan, MA; Koo, EH; Kukar, T; Ladd, T; Merit, S; Murphy, MP; Ozols, VV; Sagi, SA; Smith, TE; Weggen, S | 1 |
Behl, C; Clement, AB; Gamerdinger, M | 1 |
André, N; Bajciova, V; Deak, L; Demlova, R; Doubek, M; Dubska, L; Husek, K; Kepak, T; Kutnikova, L; Kyr, M; Martincekova, A; Mazanek, P; Mudry, P; Pavelka, Z; Skotakova, J; Sterba, J; Valik, D; Zapletalova, D; Zitterbart, K | 1 |
Bettayeb, K; Bustos, V; Flajolet, M; Galons, H; Greengard, P; Luo, W; Meijer, L; Oumata, N; Zhang, Y | 1 |
McAuley, WJ; Ng, YC; Qi, S; Yang, Z | 1 |
Allen, JC; Bendel, AE; Campigotto, F; Chi, SN; Chordas, CA; Comito, MA; Goldman, S; Hubbs, SM; Isakoff, MS; Khatib, ZA; Kieran, MW; Kondrat, L; Manley, PE; Neuberg, DS; Pan, WJ; Pietrantonio, JB; Robison, NJ; Rubin, JB; Turner, CD; Werger, AM; Zimmerman, MA | 1 |
Chang, D; Di, D; Gao, Y; Jiang, T; Liu, J; Wang, S; Zhu, W | 1 |
Dave, RH; Murdande, SB; Shah, DA | 1 |
Xie, Y; Yao, Y | 1 |
1 review(s) available for fenofibrate and celecoxib
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for fenofibrate and celecoxib
Article | Year |
---|---|
A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer.
Topics: Adolescent; Adult; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Child; Child, Preschool; Cyclophosphamide; Etoposide; Female; Fenofibrate; Follow-Up Studies; Humans; Infant; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms; Neovascularization, Pathologic; Prognosis; Prospective Studies; Pyrazoles; Sulfonamides; Survival Rate; Thalidomide; Young Adult | 2014 |
16 other study(ies) available for fenofibrate and celecoxib
Article | Year |
---|---|
Identifying off-target effects and hidden phenotypes of drugs in human cells.
Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship | 2006 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Colloid formation by drugs in simulated intestinal fluid.
Topics: Buffers; Chemical Precipitation; Colloids; Intestine, Small; Light; Microscopy, Electron, Transmission; Pharmaceutical Preparations; Scattering, Radiation; Solubility | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Abeta42 production.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Anti-Inflammatory Agents, Non-Steroidal; Aspartic Acid Endopeptidases; Brain; Celecoxib; Cell Line; Cyclooxygenase Inhibitors; Endopeptidases; Enzyme Activation; Enzyme-Linked Immunosorbent Assay; Female; Fenofibrate; Humans; Hypolipidemic Agents; Immunoprecipitation; Intracellular Signaling Peptides and Proteins; Mass Spectrometry; Protein Serine-Threonine Kinases; Pyrazoles; rho-Associated Kinases; rhoA GTP-Binding Protein; Sulfonamides; Transfection | 2005 |
Cholesterol-like effects of selective cyclooxygenase inhibitors and fibrates on cellular membranes and amyloid-beta production.
Topics: Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Amyloid Precursor Protein Secretases; Animals; Aspartic Acid Endopeptidases; Celecoxib; Cell Line, Tumor; Cell Membrane; CHO Cells; Cholesterol; Clofibrate; Cricetinae; Cricetulus; Cyclooxygenase Inhibitors; Fenofibrate; Mice; Pyrazoles; Sulfonamides | 2007 |
Metronomic chemotherapy with the COMBAT regimen in advanced pediatric malignancies: a multicenter experience.
Topics: Administration, Metronomic; Adolescent; Adult; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Child; Child, Preschool; Dacarbazine; Etoposide; Europe; Feasibility Studies; Female; Fenofibrate; Humans; Infant; Isotretinoin; Male; Neoplasms; Pyrazoles; Registries; Sulfonamides; Temozolomide; Vitamin D; Young Adult | 2012 |
Small-molecule inducers of Aβ-42 peptide production share a common mechanism of action.
Topics: Adenine; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Animals; Blotting, Western; Brain; Celecoxib; Cell Line, Tumor; Cells, Cultured; Dose-Response Relationship, Drug; Electrophoresis, Gel, Two-Dimensional; Fenofibrate; Mice; Mice, Inbred C57BL; Microscopy, Electron, Transmission; Mitochondria; Mitochondrial Proteins; Muscle Proteins; Neurons; Organic Chemicals; Peptide Fragments; Prohibitins; Protein Binding; Purines; Pyrazoles; Repressor Proteins; Roscovitine; Sulfonamides; Voltage-Dependent Anion Channel 1 | 2012 |
Stabilisation of amorphous drugs under high humidity using pharmaceutical thin films.
Topics: Carbamazepine; Celecoxib; Chemistry, Pharmaceutical; Crystallization; Drug Design; Felodipine; Fenofibrate; Humidity; Microscopy, Electron, Scanning; Polymers; Pyrazoles; Spectroscopy, Fourier Transform Infrared; Sulfonamides; Surface Properties; Temperature; Transition Temperature; Wettability | 2013 |
A geometric pore adsorption model for predicting the drug loading capacity of insoluble drugs in mesoporous carbon.
Topics: Adsorption; Carbazoles; Carbon; Carvedilol; Celecoxib; Chemistry, Pharmaceutical; Drug Carriers; Fenofibrate; Models, Chemical; Models, Molecular; Molecular Structure; Nitrogen; Nonlinear Dynamics; Porosity; Propanolamines; Reproducibility of Results; Solubility; Surface Properties; Technology, Pharmaceutical | 2015 |
Impact of nanosizing on solubility and dissolution rate of poorly soluble pharmaceuticals.
Topics: Celecoxib; Fenofibrate; Griseofulvin; Kinetics; Nanoparticles; Nanotechnology; Pharmaceutical Preparations; Solubility; Thermodynamics; Transition Temperature | 2015 |
Octenylsuccinate hydroxypropyl phytoglycogen, a dendrimer-like biopolymer, solubilizes poorly water-soluble active pharmaceutical ingredients.
Topics: Celecoxib; Dendrimers; Docetaxel; Fenofibrate; Glycogen; Griseofulvin; Pharmaceutic Aids; Resveratrol; Solubility; Solvents; Stilbenes; Succinates; Surface-Active Agents; Taxoids | 2018 |